{
    "Clinical Trial ID": "NCT00463788",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Cisplatin and Cetuximab",
        "  Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly. Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or occurrence of unacceptable toxicity.",
        "INTERVENTION 2: ",
        "  Cisplatin",
        "  Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD, unacceptable toxicity or withdrawal of consent."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically confirmed diagnosis of metastatic breast cancer (Stage IV)",
        "  Estrogen Receptor [ER] negative, PgR negative and HER2 less than 3+ expression by immunohistochemistry (IHC)",
        "  No more than 1 prior chemotherapy received for treating this metastatic breast cancer",
        "  No more than 1 prior anthracycline and/or taxane regimen (either adjuvant or metastatic setting)",
        "  Other protocol-defined inclusion criteria may apply",
        "Exclusion Criteria:",
        "  Prior platinum agent",
        "  Prior mitomycin",
        "  Known history of brain metastases",
        "  Other protocol-defined exclusion criteria may apply"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Best Overall Response (BOR)",
        "  Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).",
        "  Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009",
        "Results 1: ",
        "  Arm/Group Title: Cisplatin and Cetuximab",
        "  Arm/Group Description: Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly. Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or occurrence of unacceptable toxicity.",
        "  Overall Number of Participants Analyzed: 115",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  20.0        (13.1 to 28.5)",
        "Results 2: ",
        "  Arm/Group Title: Cisplatin",
        "  Arm/Group Description: Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD, unacceptable toxicity or withdrawal of consent.",
        "  Overall Number of Participants Analyzed: 58",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  10.3        (3.9 to 21.2)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 41/114 (35.96%)",
        "  Anaemia * 3/114 (2.63%)",
        "  Leukopenia * 1/114 (0.88%)",
        "  Thrombocytopenia * 1/114 (0.88%)",
        "  Tachycardia * 0/114 (0.00%)",
        "  Abdominal Distention * 1/114 (0.88%)",
        "  Abdomial Pain * 1/114 (0.88%)",
        "  Diarrhoea * 3/114 (2.63%)",
        "  Intestinal Obstruction * 0/114 (0.00%)",
        "  Melaena * 1/114 (0.88%)",
        "  Nausea * 2/114 (1.75%)",
        "  Vomiting * 1/114 (0.88%)",
        "  Asthenia * 2/114 (1.75%)",
        "Adverse Events 2:",
        "  Total: 13/57 (22.81%)",
        "  Anaemia * 0/57 (0.00%)",
        "  Leukopenia * 0/57 (0.00%)",
        "  Thrombocytopenia * 0/57 (0.00%)",
        "  Tachycardia * 1/57 (1.75%)",
        "  Abdominal Distention * 0/57 (0.00%)",
        "  Abdomial Pain * 0/57 (0.00%)",
        "  Diarrhoea * 0/57 (0.00%)",
        "  Intestinal Obstruction * 1/57 (1.75%)",
        "  Melaena * 0/57 (0.00%)",
        "  Nausea * 0/57 (0.00%)",
        "  Vomiting * 1/57 (1.75%)",
        "  Asthenia * 0/57 (0.00%)"
    ]
}